Continue to learn
On April 12, 2024, Chengdu Maxvax Biotechnology LLC. (hereinafter referred to as “Maxvax”) announced the IND application for its recombinant protein respiratory syncytial virus (RSV) vaccine (CHO cell) has been officially accepted by the Center for Drug Evaluation (CDE) of China’s State Drug Administration （Acceptance No.: CXSL2400228）.
more >On September 13th, 2023, the Global Health Vaccine Adjuvant Webinar, which was hosted by Global Vaccine and Immunization Research Forum (GVIRF), was successfully held. Maxvax was the only innovative vaccine company in China that was invited to attend the virtual seminar. On the meeting, Maxvax’s founder and CEO Dr. Dexiang Chen gave a presentation on Enhancing Public Health Capacity: Strengthening the Global Availability, Accessibility, and Affordability of Adjuvants and Formulations, and took part in the keynote discussion.
more >Recently, Chengdu Maxvax Biotechnology LLC. (hereinafter referred to as "Maxvax") announced the completion of its Series C financing round, raising nearly 300 million CNY.
more >On May 6, 2023, the kick-off meeting for the Phase II clinical study of Maxvax’s Recombinant Herpes Zoster Vaccine (CHO Cell) Biotechnology was successfully held in China’s northern province of Henan, and the enrollment was scheduled to be initiated on the next day.
more >Maxvax has received funding from the Bill & Melinda Gates Foundation to support the development of a low-cost HPV therapeutic vaccine candidate, aligning with global efforts to address the challenges posed by HPV infection that can lead to cervical cancer.
more >On April 18, 2023, the launching ceremony for Maxvax’s production platform for innovative vaccines was successfully held. The ceremony took place in the Life Science & Tech Park of Lingang Special Area, Shanghai. This marks that Maxvax is embarking on a new journey of commercializing its R&D achievements and demonstrates its determination and confidence to promote industrialization.
more >
On April 12, 2024, Chengdu Maxvax Biotechnology LLC. (hereinafter referred to as “Maxvax”) announced the IND application for its recombinant protein respiratory syncytial virus (RSV) vaccine (CHO cell) has been officially accepted by the Center for Drug Evaluation (CDE) of China’s State Drug Administration （Acceptance No.: CXSL2400228）.
more >
Recently, Chengdu Maxvax Biotechnology LLC. (hereinafter referred to as "Maxvax") announced the completion of its Series C financing round, raising nearly 300 million CNY.
more >
Maxvax has received funding from the Bill & Melinda Gates Foundation to support the development of a low-cost HPV therapeutic vaccine candidate, aligning with global efforts to address the challenges posed by HPV infection that can lead to cervical cancer.
more >
On September 13th, 2023, the Global Health Vaccine Adjuvant Webinar, which was hosted by Global Vaccine and Immunization Research Forum (GVIRF), was successfully held. Maxvax was the only innovative vaccine company in China that was invited to attend the virtual seminar. On the meeting, Maxvax’s founder and CEO Dr. Dexiang Chen gave a presentation on Enhancing Public Health Capacity: Strengthening the Global Availability, Accessibility, and Affordability of Adjuvants and Formulations, and took part in the keynote discussion.
more >
On May 6, 2023, the kick-off meeting for the Phase II clinical study of Maxvax’s Recombinant Herpes Zoster Vaccine (CHO Cell) Biotechnology was successfully held in China’s northern province of Henan, and the enrollment was scheduled to be initiated on the next day.
more >
On April 18, 2023, the launching ceremony for Maxvax’s production platform for innovative vaccines was successfully held. The ceremony took place in the Life Science & Tech Park of Lingang Special Area, Shanghai. This marks that Maxvax is embarking on a new journey of commercializing its R&D achievements and demonstrates its determination and confidence to promote industrialization.
more >